$MRNAModerna, Inc.

📅 Upcoming

🕒 Recent(90d)

News

• Adecto, Aviceda shut down
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 9h ago
• BioSpace 40 Under 40 winners make their mark on biopharma
  40 Under 40 honorees’ accomplishments include co-developing the world’s first synthetic biology programming language for mRNA and co-founding and leading a company acquired for $700 million up-fron…
  biospace · 21h ago
• Could we one day vaccinate against every cancer?
  What science says so far about which cancers can be beat by vaccines — and which will require more creative approaches.
  stat · 1d ago
• Sensible Bio secures $47M Series A for mRNA therapy manufacturing platform
  Sensible Biotechnologies is looking to mark its territory in the increasingly hot space of mRNA therapeutics, raising $47 million in a Series A round to develop its manufacturing approach. “Current…
  endpoints · 1d ago
• How AI is transforming biopharma manufacturing facilities of the future
  As AI accelerates drug discovery, here are the ways pharmaceutical manufacturing facilities are adapting.
  biopharma_dive · 1d ago
• STAT+: Divergent trial results on cancer vaccines have the field grappling with hard questions
  A melanoma vaccine succeeded in a late-stage clinical trial. The question now is whether other cancer vaccines will work — and whether mRNA is up to the task.
  stat · 1d ago
• What it’s like to wait for the call from the Nobel Prize committee
  Ahead of this year's Nobel Prize announcements, STAT chatted with Mary-Claire King, who discovered the BRCA cancer mutations and is frequently mentioned in prize predictions.
  stat · 4d ago
• BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
  BMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for…
  biospace · 4d ago
• Novartis wagers almost $8B on a Chinese biotech’s RNA drugs
  In exchange for a $575 million payment up front, Abogen Biosciences will furnish Novartis with access to its RNA technology, including an option to license its lead program ABO-2203.
  biopharma_dive · 4d ago
• STAT+: Lilly bypasses Australian pharmacies with DTC model
  Eli Lilly is launching LillyDirect to deliver Mounjaro straight to Australian patients’ doors — and local doctors and pharmacists aren’t thrilled.
  stat · 4d ago